Velabs is financed by Switzerland-based Xlife Sciences, is a spin-off company launched by the European Molecular Biology Laboratory and its technology transfer arm, EMBLEM Technology Transfer.

In September 2019, the firm announced that it has entered into a partnership agreement with alytas therapeutics to jointly develop modulatory and functional antibodies for an immune-based therapy against obesity.